Related Experiment Video
Updated: May 7, 2026

Clinical Protocol of Producing Adipose Tissue-Derived Stromal Vascular Fraction for Potential Cartilage Regeneration
Published on: September 29, 2018
Successful treatment of SAPHO syndrome with oral abrocitinib: a case report
Zhipeng Lin1, Songyi Piao1, Rongxin Zhang1
1Department of Dermatology, The Second Hospital of Dalian Medical University, Dalian, China.
Aim:
SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome is a rare autoimmune disorder characterized by typical cutaneous lesions (palmoplantar pustulosis and eruptive acne) and osteoarticular symptoms (aseptic osteomyelitis and joint inflammation). This study aims to evaluate the therapeutic efficacy and safety of Janus kinase 1 (JAK1) inhibitor abrocitinib in patients with SAPHO syndrome.
Methods:
We presented a patient with SAPHO syndrome with accelerated disease progression who did not respond to traditional therapies. The patient was treated with oral abrocitinib at a dosage of 100 mg daily.
Results:
After 3 months of treatment with abrocitinib, the patient exhibited considerable symptom improvement with no new facial lesions. The joint pain was completely relieved after abrocitinib administration for 15 months. No adverse events or recurrences were reported during the 18-month follow-up period.
Conclusions:
Abrocitinib monotherapy may be a promising treatment option for patients with SAPHO syndrome.
Related Concept Videos
Treatment Resistent Cancers
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:

